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ABSTRACT 
Ternary solid dispersion (TSD) is one of the promising approaches used in recent studies to address the issues encountered by poorly water-soluble 
drugs. The binary solid dispersion (BSD) with the drug and the single polymer is not sufficient to satisfy all the criteria such as improved solubility, 
dissolution, stability, supersaturation, and recrystallization inhibition. Hence, the TSD with the third component/ternary agent aids in overcoming 
the limitations, thereby enhancing the solubility and bioavailability to a greater extent when compared to the BSD. Excipients that can be used as a 
third component includes surfactants, pH modulator, polymer and adsorbents. All these excipients have distinct benefits in improving the efficiency 
of the final dosage form. However, care must be taken in selecting suitable excipients for the research. This review highlights the impact of these 
excipients in improving the formulation complications and the therapeutic potential of the TSD.  
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INTRODUCTION 
Solubility, as well as dissolution, is a fundamental principle across 
every physicochemical science, including biopharmaceutical and 
pharmacokinetic aspects of any medicine's therapy [1]. In recent 
decades, novel drugs with extraordinary medicinal benefits 
generated by various research activities entering the drug 
development phase are diminishing, due to their non-optimal 
biopharmaceutical properties [1, 2]. The foremost obstacle in the 
drug development phase is limited to the solubility/dissolution of 
the drugs in aqueous media. Since the drug must be bioavailable 
for the patient to exert its action, at a certain point of time, the 
drug must be completely dissolved or solubilized within the body 
fluid, regardless of the route of administration [3]. These 
complications significantly affect the pharmacokinetic parameter 
such as absorption, distribution, metabolism and excretion of the 
drug [4]. The primary objective of improving the 
solubility/dissolution is to enhance the bioavailability of the drug. 
The low solubility and dissolution rate of Active Pharmaceutical 
Ingredient (API) in G. I. T fluid also lead to inadequate 
bioavailability, increased dosage, and blood concentration 
variability [5]. Class II and Class IV drugs with low solubility in the 
Biopharmaceutical Classification System (BCS) suffer from 
dissolution-related absorption issues. Specific methods to resolve 
low solubility include chemical and physical alteration of drug 
candidates [6]. The Noyes-Whitney equation shows that the rate of 
dissolution of a drug is proportional to both the concentration 
gradient and the surface area of particles. Increasing the surface 
area of the substance will, therefore, increase the dissolution rate 
[7]. Several methods, such as solid dispersion (SD) [8-11], 
complexation [12, 13], lipid-based systems [14, 15], micronization 
[16, 17], nanonization [18, 19] and co-crystals [20, 21] were 
already suggested to increase the solubility of poorly water-
soluble drugs. Among them, SD technology, which involves 
dispersing drugs in different types of polymers, is commonly used 
to improve solubility and bioavailability [22]. In 1961, the SD 
principle was introduced by Sekiguchi K and Obi N [23]. 
Conventional BSD involves dispersing the drug into a single 
polymer or surfactant or any other additive, thereby enhancing the 
solubility of the drug [24]. It is known that the solid-state of the 
product may be either crystalline or amorphous, which varies with 
the energetical state of solid-packed molecules [25]. The state at 
which the drug is dispersed in the crystalline or amorphous 
carrier has a significant impact on solubility and drug release [26]. 
Although there have been consistent reports of the utilization of 
SD's in the pharmaceutical literature, only a few commercial 
products depend on the SD method [27]. An ideal formulation 
must be stable, prevent recrystallization, enhance the super 
saturation and dissolution properties of the drug. BSD may not be 
adequate for meeting all the criteria listed above [28]. Therefore, 
TSD can be an efficient technique for combating specific 
limitations of BSD [29]. TSD was formerly known as a multi-
component SD, which involves the addition of a third component 
other than the drug and a carrier (i.e., API, polymer and an 
additive) that would further enhance the efficiency of SD [30]. 
Adding a third component (ternary agent) to produce a TSD 
system gives improved stability, greater miscibility, stronger 
intermolecular interactions, significantly higher water-solubility, 
and synergistic benefit in all of these factors compared to the BSDs 
[31]. The carrier used in combination with a ternary agent could 
be a polymer, surfactant or a polymer with surfactant property 
[32, 33]. Examples of ternary agents comprise surfactant [34], 
polymer [35], adsorbent [36], pH modulator [37] and hydrotropic 
agent [38]. Various international publications of the past decade 
are summarized from the reputed source (Elsevier, Pubmed, NCBI) 
to emphasize the significance of the key components (ternary 
agents) particularly, surfactants, polymers, pH modulators, and 
adsorbents to improve TSD’s reliability in addressing the 
challenges of formulation associated with the drug solubility and 
dissolution. 
Surface active agents (surfactants) 
Surfactants are commonly used in the TSD along with the carrier as 
it provides multiple benefits. In general, the drug should reside in a 
supersaturated state to reach the optimum rate of dissolution. The 
addition of surfactants as a ternary agent results in the formation of 
complex micelles and promotes supersaturation of the drug [39]. 
Additionally, it provides improved stability and prevents the 
precipitation of the drug [40]. In TSD, the surfactant along with the 
carrier act by reducing the surface tension at the interface thereby 
alters the nature of the drug and enhances dissolution [41]. The 
Surfactant acts as a wetting agent [42], plasticizer [43], 
crystallization inhibitor [44], and stabilizer [45] with respect to 
dissolution properties [46]. Critical micellar concentration (CMC) 
and hydrophilic-lipophilic balance (HLB) play a key role in the 
dissolution of the drug [47]. When the concentration of the 
surfactant is greater than CMC, it aids in the improved dissolution by 
forming micelles/inhibiting precipitation and while lesser than CMC 
acts by reducing the interfacial tension [48-50]. Based on the 
polarity, surfactants are classified into. 
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• Non-ionic surfactants: Poloxamer, Polysorbates, Brij L4 
• Anionic surfactants: Sodium Lauryl Sulfate (SLS)/Sodium 
Dodecyl Sulfate (SDS) 
• Cationic surfactants: Cetrimide, Benzalkonium chloride 
• Amphoteric/Zwitterionic surfactants: Tocopheryl Polyethylene 
Glycol Succinate (TPGS)/Vitamin-E TPGS, Poloxamers, SLS  
The surfactants recently used in combination with carriers in TSD are 
poloxamer (Pluronic), SLS, and D-α-TPGS/Vitamin E TPGS. It is reported 
that the combination of poloxamer 188 and Polyvinyl Pyrrolidone (PVP) 
K30 showed a beneficial impact on solubility, stability, in vitro 
dissolution, and bioavailability of Febuxostat [51]. The addition of 
surfactants could be either intra-granular or extra-granular. When mixed 
intra-granularly with the API and polymer the surfactants have a 
beneficial effect on the rate of drug release rather than extra-granularly 
applied [52]. A study documented the effect of surfactant added 
internally and externally to indomethacin and PVP. Internally 
incorporated SLS had a dramatic effect on the release of indomethacin as 
compared with externally added SLS [49]. Past studies on the Surfactant-
carrier combination used in TSD are enlisted in table 1. 
 
Table 1: Studies on the surfactant-carrier combination used in TSD 
API Surfactant Carrier Impact of surfactant on TSD Ref 
Domperidone Poloxamer 188 Gelucire 50/13 
 
Poloxamer 188 was found to be an ideal ternary agent than poloxamer 407 




Poloxamer 188 PVP K30 Melt quenching of Poloxamer 188 with ezetimibe exhibited enhanced 
solubility as well supersaturation in the bio-relevant media. 
[54] 
Diacerein  Pluronic F-68 
 
PEG 4000 Pluronic F-68 in TSD enhanced the solubility of diacerein by micellar 




Pluronic F-127 PVP K30  The interfacial tension between the drug and the dissolution medium was 
minimized by surfactant in TSD which resulted in increased wettability and 
thus enhancing domperidone dissolution. 
[56] 
LW6 Poloxamer 407 Povidone K30 
 
The presence of poloxamer 407 in TSD resulted in improved solubility by 






Due to its low CMC, TPGS decreased the interfacial tension and also showed a 




TPGS Soluplus  The presence of TPGS as a plasticizer in the TSD resulted in reduced glass 
transition temperature and also enhanced penetration of the valsartan 




SDS  Soluplus 
 
The Ternary system with SDS not only enhanced the solubility and 
dissolution but also improved the bioavailability of lacidipine up to 3.7 
folds when compared to the binary system. 
[60] 
Felodipine  SDS Soluplus By acting as a plasticizer, crystallization inhibitor, a driving force to assist the 






The presence of SLS above the CMC of 2%, significantly enhanced the 




In general, water-insoluble drugs are weakly acidic or weakly basic 
compounds in nature. Hence, they mostly dependent upon the pH for 
their solubility. An approach to modify the release rate of numerous 
pH-dependent drugs is to modulate the pH of the formulation known 
as microenvironmental pH [63]. Weakly acidic drugs show greater 
solubility at neutral or alkaline pH and weakly basic drugs show 
improved solubility at acidic pH [64]. The dissolution behavior can be 
closely associated with the microenvironmental pH at the diffusion 
layer. pH modifying agents act by altering the pH through 
intermolecular hydrogen bonding with the drug and thereby 
decreasing the crystallinity of the drug resulting in an enhanced 
release rate [65]. Alkalizers [66] or Acidifiers [67] are the agents that 
can be used for altering the microenvironment pH i.e. either by 
increasing or lowering the pH at which the drug could dissolve easily. 
Alkalizers are added to weakly acidic drugs and for weakly basic drugs 
acidifiers are added. The Conventional BSD technique alone is not 
sufficient for all pH-dependent drugs as it is restricted to the 
solubilization capacity [63]. Past studies stated that combining a pH 
modulator along with a carrier in TSD could effectively enhance the 
various properties of the drugs [68-70]. A study reported that 
combining alkalizer with kollidon VA64 and glycyrrhetinic acid (GA), 
resulted in the enhanced dissolution of GA through the formation of 
ion complexes by strong electrostatic attraction [71]. Using citric acid 
(acidifier) along with Amorphous Solid Dispersion (ASD) technology 
significantly enhanced the absorption of Carvedilol even under 
elevated gastric pH conditions [72]. Some of the most commonly used 
alkalizers include Aminoclay, NaOH, Na2CO3, Ca(OH)2, NaHCO3, 
 
and 
Meglumine. Acidifiers generally used in TSD include citric acid, 
succinic acid, fumaric acid, and tartaric acid. Past studies on the pH 
modulator-carrier combination used in TSD are enlisted in table 2. 
Table 2: Studies on pH modulator-carrier combination used in TSD 
API pH modulator Carrier Impact of pH modulator on TSD Ref 
Alkalizers 
Chrysin  Aminoclay Brij L4 Chrysin (pKa 6.72) was found to be more soluble in the basic environment. Adding 
aminoclay increased the SD's microenvironment pH to the basic state, thus 
increasing the dissolution. 
[73] 
Telmisartan  NaOH Soluplus Among various alkalizer, NaOH (1%) had a beneficial impact on Telmisartan solubility 






3 The presence of Na2CO3 [75]  deprotonated the nateglinide carbonyl group, resulting in 
pH-independent solubility in the acid environment, improving the bioavailability of 
nateglinide by up to four-folds. 
Toltrazuril  Ca(OH) PVP 2 With the increase in the Ca(OH)2 ratio, the rate of dissolution of toltrazuril was 
found to be enhanced, as it facilitates intermolecular interaction with Toltrazuril 
which is necessary for the maintenance of supersaturation. 
[76] 
Clarithromycin  NaHCO HPMC/ 3 
PVP 
The Clarithromycin would have been degraded by acidic media after 60 min before 
leaving the tablet if, NaHCO3
[77] 
 were not added. The alkalizer increased the dissolution 
and stability of the drug without altering the crystallinity of the drug. 
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Since meglumine was a strong metal oxide it had a higher pH value than other 




GT0918 Citric Acid PVP  
K-30 
Citric acid aids in preventing the recrystallization of an ASD system and potentially 





Succinic acid  Kollidon-
12PF 
(PVP) 
SD with a concentration of 10% succinic acid enhanced the solubility and drug 





Fumaric acid HPMC Raloxifene HCl and fumaric acid in SD resulted in salt formation by hydrogen 









Though surrounded by enteric polymer, electrostatic interaction between tartaric 
acid and dipyridamole resulted in a change of microenvironment pH facilitating a 




Even though crystalline drugs offer the advantage of high purity and 
stability, their solubility is limited due to high lattice energy. On the 
contrary, the amorphous form depicts a disordered texture with 
high free energy that contributes to greater apparent solubility than 
its crystalline counterpart [83, 84]. Thus, the Amorphous Ternary 
Solid Dispersion (ATSD) has gained more attention in enhancing the 
solubility and dissolution properties of many poorly water-soluble 
drugs [85]. However, the pharmaceutical benefit of amorphous 
drugs is impaired by their low thermodynamic stability and their 
susceptibility to readily recrystallize in the solid-state or else during 
dissolution [86]. Retaining a drug in the amorphous state in both 
solid and solution phases is vital. The polymer prevents crystal 
growth by raising the glass transition temperature and decreasing 
the molecular mobility of the amorphous drug [87]. The polymer 
retains the supersaturated state of the drug by forming an 
intermolecular interaction with them [88]. The BSD with a drug and 
single polymer may be inadequate to satisfy all the criteria. Hence, 
the ATSD with polymer as the third component (ternary agent) is 
used to obtain optimum solubility and dissolution of poorly water-
soluble drugs [89]. TSD of Itraconazole with a combination of 
polymeric carriers such as HPMCP and soluplus prepared by hot-
melt extrusion significantly improved solubility and bioavailability 
and also retained the physical stability of the formulation [90]. PVP 
K30 was inefficient in preserving the supersaturated state of the 
drug, whereas Soluplus played an integral part in sustaining its long-
term supersaturation. Thus, PVP K30 and Soluplus had a synergistic 
effect for improving TEL's solubility and dissolution [91]. Some of 
the most commonly used combinations of polymers include HPMC, 
PVP (Kollidon), Eudragid, PLGA, and Soluplus. Past research on the 
combination of polymers used in TSD is shown in table 3. 
 
Table 3: Studies on the polymer-polymer combination used in TSD 
API Polymer Carrier Impact of polymers on TSD Ref 
Indomethacin 
 
Eudragid E100 PVP K90 
 
The SD was stabilized by Eudragid E100 and the supersaturation was retained by PVP 






Pre-dissolved HPMCAS as a powder extended the supersaturation by inhibiting 
growth over the dissolution period by maintaining the particle size. 
[89] 
Ibuprofen HPMCP-HP55 Kollidon 
VA64 
By acting as an anti-plasticizer, HPMCP HP55 increased stability and kollidon VA64 
improved the dissolution rate by increasing API wettability. 
[92] 
Griseofulvin  Soluplus Kollidon 
VA64 
Soluplus as a major component inhibited the crystal growth and a minor component 




HPMC K100 PVP K30 PVP K30 and HPMC K100 had a synergistic impact on the solid-state property and 
dissolution of both dipyridamole and cinnarizine by maximum supersaturation 
concentration and crystallization inhibition.  
[94] 
Cinnarizine  
API PVP PLGA PLGA sustained the release of the formulation by forming a phase-separated surface 
layer and PVP enhanced the solubility and dissolution of the API from the SD. 
[95] 
Clopidogrel HPMC PVP The physical stability and oral bioavailability of the drug with low glass transition 
temperature is improved by a combination of HPMC and PVP. 
[96] 
Celecoxib HPMC E5 PVP K30 The combination of PVP-HPMC prevented recrystallization and considerably improved 






HPMC As compared to the BSD of individual polymer(s), the TSD substantially increased the 
supersaturation of griseofulvin. The desired dissolution of griseofulvin is 




Despite several advantages, TSD has certain drawbacks due to its 
handling and stability issues. TSD formulation often results in a waxy 
yield, and this is due to the carrier’s nature. As a result, they tend to 
have a poor flow, poor compressibility, and hard to pulverize [99, 
100]. To resolve these problems, inert material with good flow and 
compressibility should be used to absorb the dispersion on its surface 
[101]. Moreover, adsorption carriers not only prevent the crystal 
growth due to confined space within the pores of carriers but also 
stabilize the drug in the TSD by various chemical interactions [102]. 
Previous research has suggested that the adsorption carriers (sylysia 
350) can be used as a ternary agent in addition to their anti-
plasticizing effect in the ATSD of itraconazole [103]. Another study 
stated that using neusilin US2, as an adsorbent effectively turned 
viscous semisolid substance into a free-flowing powder so that it can 
be compressed into a tablet or filled into the capsule as powders [104]. 
The presence of neusilin US2 not only resolved the issue of TPGS's 
stickiness but also enhanced the ticagrelor flow property and the 
study revealed that the use of neusilin US2 in TSD preparation would 
improve industrial processes [105]. Some of the adsorbent widely 
used are sylysia 350 [106, 107], neusilin [108, 109], Aerosil [110, 111], 
Lactose [112, 113], Florite [114]. Past studies on the adsorbent-carrier 
combination used in TSD are enlisted in table 4. 
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Table 4: Studies on adsorbent-carrier combination used in TSD 
API Adsorbent Carrier Impact of adsorbents on TSD Ref 
Valsartan Lactose Gelucire 50/13 Increased quantity of lactose addition resulted in free-flowing powder with 
reproducible dissolution characteristics. 
[100] 
Bosentan Sylysia 350 Poloxamer 188 The inclusion of Sylysia 350 turned the waxy SD into a free-flowing powder 
with adequate compressibility and also expanded the surface area, resulting in 




Sylysia 350 Gelucire 50/13 The benefits of adding sylysia 350 are better yield, inhibition of 
recrystallization, flowability, an increase in the effective surface area, and 




Neusilin US2 Phosphatidylcholine 
(PC) 
As the PC-based SD exhibited a lipidic consistency, it was challenging 
to formulate it into an oral dosage form. The flowability of the SD was 




Neusilin UFL2 Kollidon VA64 
 
Together with the carrier, Neusilin UFL2 improved the dissolution by 
increasing the surface area and carbamazepine flowability. 
[108] 
Curcumin Aerosil Gelucire 50/13 
 
Due to the hydrogen bonding between the drug and the carrier and its surface 
adsorption onto the aerosil, the TSD was found to be stable for around 9 mo. 
[109] 
Nifedipine Aerosil 200 Eudragit E The absence of adsorbent resulted in a gelatinous mass, while free-flowing 
powder was observed along with a significant increase in dissolution in the 
presence of Aerosil 200. 
[110] 
Gliclazide Lactose Poloxamer/ 
PEG 
Complete desorption of gliclazide resulted in rapid dissolution by the 




Florite  Poloxamer 188 Florite prevented the transformation of an amorphous form to a crystalline 




Various additives are used as a third component to overcome the 
limitations associated with BSD. These additives improve the 
efficiency of TSD as a formulation through several strategies. For 
example, surfactants along with the carrier act by distinct 
mechanisms such as reducing the surface tension, preventing 
recrystallization, maintenance of supersaturation and also improves 
the physical stability of the drug. CMC and HLB are the important 
variables to be considered when selecting a surfactant for the study. 
Therefore, care must be taken in choosing suitable surfactants. For 
drugs that depend on the pH for their solubility, pH modulators are 
the appropriate choice of excipients. Alkalizers/acidifiers aids in 
solubility and dissolution of weakly acidic/weakly basic drugs by 
modulating the microenvironment pH at which the drug dissolves 
easily.  
They also assist in supersaturation by establishing an intermolecular 
interaction with the drug. Additionally, pH modulators improved 
stability without altering the nature of the formulation. The 
amorphous form of the drug offers improved apparent solubility than 
its crystalline counterpart owing to its high free energy. Since the 
ATSDs are thermodynamically unstable and more liable to 
recrystallization, it is vital to maintain them in the amorphous state. 
The polymer-polymer combination aids in maintaining the super 
saturation, inhibiting the crystal growth, and improved the stability of 
the ATSD. Despite enormous benefits, the commercial use of SD is 
limited due to the complexity of handling and scale-up. To overcome 
these obstacles, adsorbents are added to the TSD as a third 
component. These adsorbents convert the waxy SD into a free-flowing 
powder so that it can be compressed into a tablet or powder that can 
be filled into the capsule. Every excipient has both benefits and 
drawbacks, so caution should be given to selecting the appropriate 
excipient for the research. It is therefore concluded that the addition of 
different additives as a third component improves TSD's efficacy in 
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